share_log

復星醫藥:海外監管公告-關於股份回購事項前十大股東和前十大無限售條件股東持股情況的公告

FOSUN PHARMA: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

香港交易所 ·  Apr 2 05:50
Summary by Moomoo AI
上海復星醫藥於2024年3月26日召開董事會,通過以集中競價交易方式回購公司股份的方案,並於次日在上海證券交易所網站公布相關細節。根據相關規定,公司公告了截至2024年3月26日收市的前十大股東及前十大無限售條件股東的持股情況。其中,上海復星高科技(集團)有限公司為最大股東,持股比例為33.17%,HKSCC NOMINEES LIMITED持股20.63%。該回購行動旨在增強股東價值並展現對公司未來發展的信心。
上海復星醫藥於2024年3月26日召開董事會,通過以集中競價交易方式回購公司股份的方案,並於次日在上海證券交易所網站公布相關細節。根據相關規定,公司公告了截至2024年3月26日收市的前十大股東及前十大無限售條件股東的持股情況。其中,上海復星高科技(集團)有限公司為最大股東,持股比例為33.17%,HKSCC NOMINEES LIMITED持股20.63%。該回購行動旨在增強股東價值並展現對公司未來發展的信心。
Shanghai Fustar Pharmaceuticals convened the Board of Directors on March 26, 2024 to repurchase the company's shares through a centralized tender transaction and announced the details on the Shanghai Stock Exchange website the next day. Pursuant to the relevant provisions, the Company announces the holding status of the top 10 shareholders and the top 10 unrestricted offer shareholders as of March 26, 2024. OF THESE, SHANGHAI FUSTAR HIGH TECHNOLOGY (GROUP) LIMITED IS THE LARGEST SHAREHOLDER WITH A SHAREHOLDING OF 33.17% AND HKSCC NOMINEES LIMITED HOLDING 20.63%. The repurchase is designed to enhance shareholder value and demonstrate confidence in the future of the company.
Shanghai Fustar Pharmaceuticals convened the Board of Directors on March 26, 2024 to repurchase the company's shares through a centralized tender transaction and announced the details on the Shanghai Stock Exchange website the next day. Pursuant to the relevant provisions, the Company announces the holding status of the top 10 shareholders and the top 10 unrestricted offer shareholders as of March 26, 2024. OF THESE, SHANGHAI FUSTAR HIGH TECHNOLOGY (GROUP) LIMITED IS THE LARGEST SHAREHOLDER WITH A SHAREHOLDING OF 33.17% AND HKSCC NOMINEES LIMITED HOLDING 20.63%. The repurchase is designed to enhance shareholder value and demonstrate confidence in the future of the company.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more